TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04931277

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
Study: NCT06158412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans Retinoic Acid in combination with the KPD Regimen
Description: Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day.
Study: NCT05463757

Intervention type: DRUG
Intervention: Vismodegib
Description: Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)

Intervention type: DRUG
Intervention: Sonidegib
Description: Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
Study: NCT05357521

Intervention type: OTHER
Intervention: stress test
Description: TSST- psychosocial stress test

Intervention type: OTHER
Intervention: stress test
Description: TSST- psychosocial stress test
Study: NCT06070142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP Group
Description: Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eTEP Group
Description: Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
Study: NCT05480072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21
Study: NCT06448923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 25 mg of CBD tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 50 mg of CBD tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets twice daily
Study: NCT05805033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mucointegration
Description: Placement of abutment on a dental implant to study mucointegration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mucointegration
Description: Placement of abutment on a dental implant to study mucointegration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mucointegration
Description: Placement of abutment on a dental implant to study mucointegration
Study: NCT04989348

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gonadotrophin releasing hormone antagonist protocol
Description: Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progestin-primed ovarian stimulation protocol
Description: Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
Study: NCT06434571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth cognitive behavioral therapy for insomnia (tCBT-I)
Description: The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy for insomnia (wCBT-I)
Description: Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
Study: NCT05354726

Intervention type: OTHER
Intervention: Assessments parameters
Description: Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength

Intervention type: OTHER
Intervention: Assessments parameters
Description: Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
Study: NCT04367675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-5401
Description: INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
Study: NCT04537247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial nephrectomy for complex renal tumor
Description: removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial nephrectomy for complex renal tumor
Description: removal of tumor with sufficient safety margin with preservation of functioning renal unit (renal tissue with its collecting system, arterial supply and venous as well as lymphatic drainage).
Study: NCT02861183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OVT (Sodium Hyaluronate)
Description: A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
Study: NCT05994781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyDew MD regen cram
Description: No intervention
Study: NCT04367675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-5401
Description: INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000
Description: The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
Study: NCT05617820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Vaginal Insert, 4 mcg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imvexxy
Description: Estradiol 4 mcg Vaginal Insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Vaginal Insert
Study: NCT06432621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation
Description: patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using of sugammadex and neostigmine for reversal from rocuronium and assessment of response using ultrasound and nerve stimulation
Description: patients will be randomly divided into two groups using a computer generated random number chart. Group S will receive sugammadex for reversal of rocuronium, whereas Group N will receive neostigmine for reversal of rocuronium using nerve stimulation and ultrasound to asses recovery of respiratory muscle
Study: NCT06482710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinwheel
Description: The children in the intervention group were given breathing exercises with pinwheels.
Study: NCT05717829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified hip capsular incision
Description: modified incision to make re -suturing of the capsule easier with multiple stitches.
Study: NCT06222463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evone
Description: Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evone
Description: Evone (Ventinova Medical B.V., Eindhoven, The Netherlands) is a ventilator, which is able to perform flow-controlled ventilation (FCV). Moreover it provides direct tracheal pressure measurements and combined with the constant gas flow of FCV a precise determination of dynamic compliance is feasible. Thus not only PEEP but also peak pressure can be titrated based on dynamic compliance. Additionally intratracheal pressure-volume loops can be measured and thus power dissipation calculated, which represents the primary outcome parameter of this trial.
Study: NCT05719714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG [Farxiga]
Description: 10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.
Study: NCT04765033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized 5% Hypertonic saline
Description: nebulized 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 5% Hypertonic saline
Description: nebulized 0.9% saline
Study: NCT05710302

Intervention type: OTHER
Intervention: Investigation of the diagnostic accuracy of EHMRG risk score in patients with acute heart failure
Description: Prospective validation of the EHMRG score in patients with acute heart failure in the emergency department
Study: NCT04367675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000
Description: The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
Study: NCT06459609

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplementation
Description: Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplementation
Description: Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
Study: NCT05440045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MW3211
Description: 6MW3211 injection, 30mg/kg, Q2W
Study: NCT05772949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group intervention
Description: The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wait-list control group intervention
Description: The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids.
Study: NCT06777238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05378399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy or Truvada
Description: Descovy or Truvada prescribed with digital pills for PrEP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Cap System
Description: Digital pills overencapsulating Descovy or Truvada for PrEP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beiwe
Description: Digital phenotyping app
Study: NCT05495854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCR test in the stool
Description: Patients randomized to the new strategy arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
Study: NCT06060028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interoceptive stimulation treatment with mechanical stimulation of C-LTMRs afferences
Description: The intervention is a non-invasive interoceptive stimulation (affective touch) delivered to the left volar forearm. The stimulation is delivered using a device with a small tactile probe that touches the skin in a circular motion. The device is designed to induce maximum firing frequency in the peripheral C-Ts nervous afferents, which respond to low-force, low-velocity stimuli, specifically 3 cm/sec, 2.5mN. The stimulation will be delivered in 18 blocks, each consisting of 6 short periods of stimulation of varying durations presented in random order, with pauses of 6 seconds after every single stimulation, the entire stimulation protocol will have a total duration of 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: In the sham condition, patients will receive a similar stimulation with the interoceptive tactile device, however, the device will be turned on for only 3 seconds every minute, and consequently turned off for 57 seconds. The entire duration of the stimulation will be approximately 30 minutes, similar to the experimental condition.
Study: NCT06323824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Drug: Methadone~Possible formulations:~10 and 40 mg tablets
Study: NCT06633263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Introduce self-recording with the sleep diary; Introduce basic notions of insomnia; Introduce basic notions of sleep hygiene; Introduce basic notions of sleep; Recreate a time and place dedicated to sleep; Limit time spent in bed to time slept; Promote attitudes and beliefs that favor sleep and manage worries; Relapse prevention. This intervention is empirically validated (Morin, 2022).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression
Description: Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression
Description: Introduce self-recording with daily activities; Introduce the basic concept of depression; Identify and increase activities associated with positive reinforcement; Reflect on life domains and values to identify reinforcing activities; Identify and decrease activities associated with negative reinforcement; Identify and decrease activities associated with negative reinforcement; Relapse prevention. This intervention is empirically validated (Ciharova et al., 2021)
Study: NCT05816122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSCopilot® Detect mobile application
Description: MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
Study: NCT05975385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at points points PC 6 bilaterally, LI 4 bilaterally, and Yin Tang
Study: NCT06059716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten detection technology
Description: Portable technology to sense gluten after ingestion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous telemedicine monitoring
Description: Regular follow-up with an expert dietitian
Study: NCT05890326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Description: Pain neuroscience education (PNE) is a health education intervention that aims to provide up-to-date information on neuroscience developments in the field of chronic pain. All patients were trained once a week for 12 weeks, in groups of 3-4 people, for a maximum of 6 sessions and a minimum of 60 minutes. During the intervention, psychological factors such as self-efficacy, pain intervention/injury, coping with pain, catastrophic thoughts, emotional response to pain, anxiety, frustration/anger, fear of harm, concerns about pain, and fear of pain were examined. and discussed with patients. The sessions aimed to provide patients with a better understanding of their chronic pain by addressing the multifactorial aspects of chronic pain, sensitization and the plasticity of the brain, thus involving patients in treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery-based exercise protocol (MIEP)
Description: All patients performed sessions of maximum 60 minutes in groups of 3-4 people twice a week for 12 weeks. This study protocol was developed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. The key standard was to practice simple and safe exercises that would encourage the patient to repeat the program at home. The exercises proposed in MIEP were selected according to the following principles: slowness, painlessness, arousing attention, easy to imagine. The main purpose of the motor imagery exercises was to bring the patient back to the state of feeling and self-perception of the execution of the movement. More important than the quantity of repetition was the painless quality of movement. It was performed in 3 phases: relaxation (3 minutes), MI (8.5 minutes per image) and refocus (3 minutes), which included both kinesthetic imagery (KI) and visual imagery (VI).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combination Group
Description: Subjects received 6 sessions of Pain neuroscience education (PNE) and 12 weeks (2 times a week) of Motor imagery-based exercise protocol (MIEP).
Study: NCT05606692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1%
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.